Whetstone Capital Advisors LLC Boosts Holdings in LifeMD, Inc. $LFMD

Whetstone Capital Advisors LLC raised its stake in shares of LifeMD, Inc. (NASDAQ:LFMD) by 89.6% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 703,053 shares of the company’s stock after purchasing an additional 332,269 shares during the period. LifeMD accounts for 0.7% of Whetstone Capital Advisors LLC’s holdings, making the stock its 23rd biggest position. Whetstone Capital Advisors LLC owned about 1.46% of LifeMD worth $2,397,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in the stock. Verition Fund Management LLC lifted its holdings in LifeMD by 62.0% during the fourth quarter. Verition Fund Management LLC now owns 54,893 shares of the company’s stock valued at $187,000 after purchasing an additional 21,004 shares in the last quarter. MYDA Advisors LLC purchased a new position in LifeMD during the fourth quarter valued at $512,000. Barclays PLC lifted its holdings in LifeMD by 13.6% during the fourth quarter. Barclays PLC now owns 61,028 shares of the company’s stock valued at $208,000 after purchasing an additional 7,300 shares in the last quarter. Caitong International Asset Management Co. Ltd purchased a new position in LifeMD during the fourth quarter valued at $36,000. Finally, Wells Fargo & Company MN lifted its holdings in LifeMD by 71.4% during the fourth quarter. Wells Fargo & Company MN now owns 44,162 shares of the company’s stock valued at $151,000 after purchasing an additional 18,396 shares in the last quarter. 35.52% of the stock is owned by hedge funds and other institutional investors.

LifeMD Price Performance

Shares of LFMD stock opened at $4.70 on Monday. The firm’s 50-day moving average is $4.36 and its two-hundred day moving average is $3.80. LifeMD, Inc. has a 12 month low of $2.56 and a 12 month high of $15.84. The company has a market capitalization of $227.29 million, a PE ratio of 94.02 and a beta of 1.98.

LifeMD (NASDAQ:LFMD) last issued its earnings results on Wednesday, May 6th. The company reported ($0.20) EPS for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.06). LifeMD had a negative return on equity of 150.88% and a net margin of 2.37%.The firm had revenue of $50.16 million for the quarter, compared to analysts’ expectations of $48.84 million. Sell-side analysts forecast that LifeMD, Inc. will post -0.37 EPS for the current year.

Wall Street Analysts Forecast Growth

LFMD has been the topic of several research reports. Loop Capital set a $10.00 price target on shares of LifeMD in a research note on Thursday, March 12th. BTIG Research reissued a “buy” rating and issued a $10.00 price target on shares of LifeMD in a research note on Monday, May 4th. Mizuho raised shares of LifeMD from a “neutral” rating to an “outperform” rating and raised their price target for the stock from $6.00 to $8.00 in a research note on Monday, March 16th. Cantor Fitzgerald reissued an “overweight” rating on shares of LifeMD in a research note on Tuesday, March 10th. Finally, Weiss Ratings raised shares of LifeMD from a “sell (e+)” rating to a “sell (d)” rating in a research note on Thursday, May 7th. Eight research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $9.14.

About LifeMD

LifeMD (NASDAQ: LFMD) is a U.S.-based telehealth company that delivers on-demand, membership-based virtual healthcare services. Through its digital platform and mobile applications, LifeMD connects patients with board-certified healthcare providers for diagnosis, treatment and ongoing management of a range of acute and chronic conditions. The company’s core offering centers on personalized care plans supported by prescription fulfillment, lab testing and prescription delivery services.

LifeMD’s service portfolio spans several specialty areas, including men’s health, hormonal therapy, weight management and primary care.